Patents
US 12741035 B2: Utilization of gene targeting antibody fusion proteins to perform in vivo therapeutic gene editing
- Granted
- 2026-09-22
- Filed
- 2025-03-28 application 19094456
- Type
- Utility · 18 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Embodiments of the present disclosure concerns methods and compositions related to treatment using a CRISPR/Cas9/targeting antibody/gene targeting small guide RNA (sgRNA) fusion protein/ribonucleotide complex. The targeting of a polynucleotide of interest, such as a gene, may be effective to eradicate tumors in mammals. In some cases, sgRNA ribonucleotides with sequences designed to target any gene or genomic region are contemplated. In some embodiments, the targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR-based gene modification in vivo obviating the need for adoptive cell therapy. In some cases, substitutions of the CD25 targeting antibody is replaced with another antibody to recognize other cell surface antigens. In some cases, sgRNA ribonucleotides with sequences designed to target any gene or genomic region are described.
Source: PTBLXML, file of 2026-09-22 (ipgb20260922.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Baylor College of Medicine 276 patents | US company or organization | Houston, TX | Baylor College of Medicine College or university EXACT high confidence: identical full name and state BAYLOR COLLEGE OF MEDICINE Nonprofit EXACT high confidence: identical full name and state | PTBLXML, file of 2026-09-22 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| David M. Lonard | Houston, TX | PTBLXML, file of 2026-09-22 | ||
| Bert W. O'Malley | Houston, TX | 19 | PTBLXML, file of 2026-09-22 | |
| Clifford Dacso | Houston, TX | 7 | PTBLXML, file of 2026-09-22 | |
| Sang Jun Han | Houston, TX | 4 | PTBLXML, file of 2026-09-22 | |
| Rohit Kumar Srivastava | Houston, TX | PTBLXML, file of 2026-09-22 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| A61K | Preparations for medical, dental or toiletry purposes | A61K48/005 | PTBLXML, file of 2026-09-22 |
| C07K | Peptides | C07K16/2866 | PTBLXML, file of 2026-09-22 |
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N9/226 | PTBLXML, file of 2026-09-22 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
No recorded assignments or security interests on file for this patent.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.